Last reviewed · How we verify

NCT07180251

Impact of Glycemic Variability on People With Gastrointestinal Cancer and Diabetes After Surgery

Active, enrolled NA Last updated 18 September 2025
What this trial tests

NA trial testing CARE program in Diabetes Melletus in 260 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
8 September 2025
Primary endpoint
31 July 2028
31 July 2028

Quick facts

Lead sponsorNational Taiwan University Hospital
PhaseNA
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposesupportive care
Enrollment260
Start date8 September 2025
Primary completion31 July 2028
Estimated completion31 July 2028
Sites1 location across Taiwan

Drugs / interventions tested

Conditions studied

Sponsor

National Taiwan University Hospital

Who can join

18 and older, any sex, with Diabetes Melletus or Gastrointestinal Cancers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In study phase 1, the investigators will prospectively examine the factors related to post-operative glycemic variability and its effect on outcomes in people with both DM and GI cancer after surgery. The study will also qualitatively understand the glycemic variability experiences and their associated symptoms and outcomes in people with both DM and GI cancer. In study phase 2, the investigators will develop and test the effects of the CGM-Assisted Reflection Education (CARE) program on adults with both DM and GI cancer post-surgery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other National Taiwan University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07180251.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing